» Articles » PMID: 15578093

Novel APC-like Properties of Human NK Cells Directly Regulate T Cell Activation

Abstract

Initiation of the adaptive immune response is dependent on the priming of naive T cells by APCs. Proteomic analysis of unactivated and activated human NK cell membrane-enriched fractions demonstrated that activated NK cells can efficiently stimulate T cells, since they upregulate MHC class II molecules and multiple ligands for TCR costimulatory molecules. Furthermore, by manipulating antigen administration, we show that NK cells possess multiple independent unique pathways for antigen uptake. These results highlight NK cell-mediated cytotoxicity and specific ligand recognition by cell surface-activating receptors on NK cells as unique mechanisms for antigen capturing and presentation. In addition, we analyzed the T cell-activating potential of human NK cells derived from different clinical conditions, such as inflamed tonsils and noninfected and CMV-infected uterine decidual samples, and from transporter-associated processing antigen 2-deficient patients. This in vivo analysis revealed that proinflammatory, but not immune-suppressive, microenvironmental requirements can selectively dictate upregulation of T cell-activating molecules on NK cells. Taken together, these observations offer new and unexpected insights into the direct interactions between NK and T cells and suggest novel APC-like activating functions for human NK cells.

Citing Articles

Obtaining Gene-Modified HLA-E-Expressing Feeder Cells for Stimulation of Natural Killer Cells.

Alekseeva N, Streltsova M, Vavilova J, Ustiuzhanina M, Palamarchuk A, Boyko A Pharmaceutics. 2024; 16(1).

PMID: 38276503 PMC: 10818548. DOI: 10.3390/pharmaceutics16010133.


Identification of transient receptor potential melastatin 3 proteotypic peptides employing an efficient membrane protein extraction method for natural killer cells.

Magawa C, Eaton-Fitch N, Balinas C, Martini Sasso E, Thapaliya K, Barnden L Front Physiol. 2022; 13:947723.

PMID: 36213251 PMC: 9540229. DOI: 10.3389/fphys.2022.947723.


Functional NK Cell Activation by Ovalbumin Immunization with a Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Dendritic Cell Maturation.

Le C, Ahn S, Kang S, Ko E Vaccines (Basel). 2021; 9(10).

PMID: 34696169 PMC: 8540815. DOI: 10.3390/vaccines9101061.


Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.

Hervier B, Ribon M, Tarantino N, Mussard J, Breckler M, Vieillard V Front Immunol. 2021; 12:633658.

PMID: 34012432 PMC: 8126610. DOI: 10.3389/fimmu.2021.633658.


Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells.

Chrobok M, Dahlberg C, Sayitoglu E, Beljanski V, Nahi H, Gilljam M Cancers (Basel). 2019; 11(1).

PMID: 30634595 PMC: 6356567. DOI: 10.3390/cancers11010069.


References
1.
Markel G, Mussaffi H, Ling K, Salio M, Gadola S, Steuer G . The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood. 2003; 103(5):1770-8. DOI: 10.1182/blood-2003-06-2114. View

2.
Schjetne K, Thompson K, Nilsen N, Flo T, Fleckenstein B, Iversen J . Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol. 2003; 171(1):32-6. DOI: 10.4049/jimmunol.171.1.32. View

3.
Homann D, Jahreis A, Wolfe T, Hughes A, Coon B, van Stipdonk M . CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity. 2002; 16(3):403-15. DOI: 10.1016/s1074-7613(02)00290-x. View

4.
Perkins D, Pappin D, Creasy D, Cottrell J . Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20(18):3551-67. DOI: 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2. View

5.
Blattman J, Greenberg P . Cancer immunotherapy: a treatment for the masses. Science. 2004; 305(5681):200-5. DOI: 10.1126/science.1100369. View